Illumina, Inc.
Illumina Announces Preliminary Financial Results for Q4 and FY 2024
Summary
Illumina, Inc. has announced its preliminary unaudited financial results for the fourth quarter and fiscal year ended December 29, 2024. The company reported a revenue of approximately $1.10 billion for Q4 2024, a slight increase of 1% from Q4 2023, and a revenue of approximately $4.33 billion for 2024, a 2% decrease from 2023 on a constant currency basis. The GAAP operating margin was approximately 16.7% for Q4 2024 and 34.2% for 2024, while the non-GAAP operating margin was approximately 19.7% for Q4 2024 and 21.3% for 2024. The company also provided a preliminary outlook for fiscal year 2025, expecting constant currency revenue growth in the low single digits, a non-GAAP operating margin of approximately 23%, and non-GAAP diluted EPS growth of approximately 10%. The full financial results will be reported on February 6, 2025.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement